Topical Ocular Mecamylamine in Diabetic Macular Edema (DME)

• Status: Completed
• Trial end date: 2008-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This is an open-label study evaluating the safety and tolerability of topical ocular mecamylamine given twice a day in patients with diabetic macular edema (DME). Patients will be treated for 12 weeks.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: CoMentis
• Collaborator: Juvenile Diabetes Research Foundation
• Treatments: Mecamylamine

Criteria

Inclusion Criteria:

• macular edema due to diabetic retinopathy

Exclusion Criteria:

• vision loss from other ocular disease

• intraocular surgery within 3 months

• intraocular anti-VEGF or steroids within 3 months

• HbA1c >12